Catalent, Inc. (NYSE:CTLT – Get Rating) – Zacks Research lowered their Q3 2023 EPS estimates for Catalent in a note issued to investors on Tuesday, May 9th. Zacks Research analyst D. Dey now anticipates that the company will post earnings per share of ($0.32) for the quarter, down from their prior forecast of $0.71. The consensus estimate for Catalent’s current full-year earnings is $2.60 per share. Zacks Research also issued estimates for Catalent’s Q4 2023 earnings at $0.76 EPS, FY2023 earnings at $1.37 EPS, Q2 2024 earnings at $0.41 EPS, Q3 2024 earnings at $0.40 EPS, Q4 2024 earnings at $1.12 EPS, FY2024 earnings at $2.13 EPS, Q1 2025 earnings at $0.42 EPS, Q3 2025 earnings at $0.74 EPS and FY2025 earnings at $3.18 EPS.
CTLT has been the topic of a number of other research reports. Bank of America lowered shares of Catalent from a “neutral” rating to an “underperform” rating and set a $28.00 price objective on the stock. in a research note on Monday. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Catalent from $72.00 to $55.00 in a report on Tuesday. Barclays cut their price target on Catalent from $70.00 to $40.00 in a report on Monday, April 17th. Morgan Stanley raised their price objective on Catalent from $81.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, February 9th. Finally, StockNews.com raised Catalent to a “sell” rating in a research note on Saturday, April 15th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Catalent has a consensus rating of “Hold” and an average target price of $77.40.
Catalent Stock Performance
Shares of CTLT stock opened at $34.19 on Friday. The company has a market cap of $6.16 billion, a P/E ratio of 15.13, a PEG ratio of 2.38 and a beta of 1.17. The business has a 50 day moving average of $57.51 and a two-hundred day moving average of $54.47. Catalent has a 52 week low of $32.41 and a 52 week high of $115.33. The company has a quick ratio of 1.38, a current ratio of 1.91 and a debt-to-equity ratio of 0.86.
Catalent (NYSE:CTLT – Get Rating) last announced its quarterly earnings data on Tuesday, February 7th. The company reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.64 by ($0.02). Catalent had a return on equity of 11.40% and a net margin of 8.62%. The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.12 billion.
Insider Buying and Selling
In other news, insider Manja Boerman sold 1,446 shares of the stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $72,097.56. Following the transaction, the insider now owns 14,414 shares in the company, valued at $718,682.04. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Catalent news, SVP Mario Gargiulo sold 678 shares of the stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $33,805.08. Following the completion of the transaction, the senior vice president now directly owns 5,676 shares in the company, valued at $283,005.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Manja Boerman sold 1,446 shares of the business’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $72,097.56. Following the sale, the insider now owns 14,414 shares in the company, valued at $718,682.04. The disclosure for this sale can be found here. 0.58% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Catalent
Large investors have recently modified their holdings of the business. Cetera Advisor Networks LLC grew its position in Catalent by 7.1% in the 1st quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock valued at $217,000 after purchasing an additional 130 shares during the period. Mackay Shields LLC grew its stake in Catalent by 0.6% in the 1st quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock worth $2,856,000 after buying an additional 149 shares in the last quarter. Texas Permanent School Fund grew its position in Catalent by 0.8% during the fourth quarter. Texas Permanent School Fund now owns 25,569 shares of the company’s stock valued at $1,151,000 after acquiring an additional 212 shares during the last quarter. Global Strategic Investment Solutions LLC increased its stake in Catalent by 3.4% in the 4th quarter. Global Strategic Investment Solutions LLC now owns 6,937 shares of the company’s stock worth $312,000 after purchasing an additional 229 shares during the period. Finally, Czech National Bank grew its holdings in Catalent by 1.1% in the 4th quarter. Czech National Bank now owns 21,065 shares of the company’s stock worth $948,000 after acquiring an additional 238 shares during the last quarter. Institutional investors own 99.38% of the company’s stock.
About Catalent
(Get Rating)
Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Catalent, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Catalent wasn’t on the list.
While Catalent currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
